Welcome to our dedicated page for MYCO news (Ticker: MYCO), a resource for investors and traders seeking the latest updates and insights on MYCO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MYCO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MYCO's position in the market.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has announced an increase in its bought deal financing, raising C$15 million by offering 30 million units at C$0.50 each, with a closing date set for February 3, 2021. Each unit consists of one common share and a warrant, exercisable at $0.70 for 36 months. An over-allotment option allows for an additional 4.5 million units, potentially increasing proceeds to C$17.25 million. Funds will be used for clinical trials, expanding intellectual property, and ongoing operations.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has announced a bought deal agreement with Canaccord Genuity to purchase 20,000,000 units at C$0.50 each, totaling gross proceeds of C$10 million. Each unit consists of one common share and one purchase warrant. There is an Over-Allotment Option for an additional 3 million units, potentially increasing total proceeds to C$11.5 million. The proceeds will fund clinical trials, intellectual property expansion, and general working capital. Closing is anticipated on February 3, 2021, pending regulatory approvals.
